{"nctId":"NCT00857584","briefTitle":"Quetiapine XR Versus Sertraline in Acute Bipolar Depression as add-on Therapy","startDateStruct":{"date":"2009-05"},"conditions":["Bipolar Disorder","Bipolar Depression"],"count":27,"armGroups":[{"label":"Quetiapine Extended Release","type":"EXPERIMENTAL","interventionNames":["Drug: Extended release quetiapine (quetiapine XR)","Drug: adequate mood stabilizer"]},{"label":"Sertraline","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Sertraline","Drug: adequate mood stabilizer"]}],"interventions":[{"name":"Extended release quetiapine (quetiapine XR)","otherNames":["SEROQUEL XR®"]},{"name":"Sertraline","otherNames":["Zoloft"]},{"name":"adequate mood stabilizer","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult ambulatory patients diagnosed of bipolar disorder I or II, current depressive episode (DSM-IV-TR 4ª Ed: 296.5x or 296.89 codes)\n* Have been treated with only one mood stabilizer (lithium or valproate) in optimal and stable doses during at least the previous 4 weeks to randomization\n* Hamilton Depression Rating Scale (HDRS-17) total score ≥ 20 and Young Mania Rating Scale (YMRS) total score ≤ 14 at the screening and randomization visits - Informed consent signed\n\nExclusion Criteria:\n\n* Patients with any axis I or II Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR) diagnoses different from bipolar disorder I or II - Length of current depressive episode less than 2 weeks or more than 12 months\n* Having been treated with more than one mood stabilizer or any mood stabilizer other than Lithium or valproate, any antidepressant, any antipsychotic or any CP450-3A inductor/inhibitor within the 7 days period prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Mean Change From Baseline to Week 2 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","description":"MADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.1","spread":null},{"groupId":"OG001","value":"-6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 1 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","description":"MADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":null},{"groupId":"OG001","value":"-8.6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 4 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","description":"MADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.1","spread":null},{"groupId":"OG001","value":"-17.7","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 8 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score","description":"MADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-19.4","spread":null},{"groupId":"OG001","value":"-18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 1 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score","description":"CGI-BP-M assesses severity of clinical status. It ranges from a minimum of 1 to a maximum of 7 ( higher scores indicating a greater clinical severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.79","spread":null},{"groupId":"OG001","value":"-1.08","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 2 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score","description":"CGI-BP-M assesses severity of clinical status. It ranges from a minimum of 1 to a maximum of 7 ( higher scores indicating a greater clinical severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.36","spread":null},{"groupId":"OG001","value":"-1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 4 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score","description":"CGI-BP-M assesses severity of clinical status. It ranges from a minimum of 1 to a maximum of 7 ( higher scores indicating a greater clinical severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.09","spread":null},{"groupId":"OG001","value":"-2.56","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 8 in the Clinical Impression Global Scale - Bipolar (CGI-BP-M) Total Score","description":"CGI-BP-M assesses severity of clinical status. It ranges from a minimum of 1 to a maximum of 7 (higher scores indicating a greater clinical severity)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":null},{"groupId":"OG001","value":"-2.88","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 4 in the Hamilton Anxiety Rating Scale (HARS) Total Score","description":"HARS assesses severity of anxiety symptoms. It ranges from a minimum of 0 to a maximum of 56 (higher scores indicating a greater severity of anxiety symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.4","spread":null},{"groupId":"OG001","value":"-8.9","spread":null}]}]}]},{"type":"SECONDARY","title":"The Mean Change From Baseline to Week 8 in the Hamilton Anxiety Rating Scale (HARS) Total Score","description":"HARS assesses severity of anxiety symptoms. It ranges from a minimum of 0 to a maximum of 56 (higher scores indicating a greater severity of anxiety symptoms)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.1","spread":null},{"groupId":"OG001","value":"-10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Response at Week 1","description":"Number of patients responded to the treatment at week 1, where response is defined as ≥ 50% reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to week 1.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Response at Week 2","description":"Number of patients responded to the treatment at week 2, where response is defined as ≥ 50% reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to week 2.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Response at Week 4.","description":"Number of patients responded to the treatment at week 4, where response is defined as ≥ 50% reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to week 4.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Response at Week 8.","description":"Number of patients responded to the treatment at week 8, where response is defined as ≥ 50% reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score from baseline to week 8.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Remission at Week 1.","description":"Number of patients who achieved remission at week 1, where remission is defined as Montgomery Asberg Depression Rating Scale (MADRS) total score ≤ 10.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Remission at Week 2.","description":"Number of patients who achieved remission at week 2, where remission is defined as Montgomery Asberg Depression Rating Scale (MADRS) total score ≤ 10.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Remission at Week 4.","description":"Number of patients who achieved remission at week 4, where remission is defined as Montgomery Asberg Depression Rating Scale (MADRS) total score ≤ 10.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Remission at Week 8.","description":"Number of patients who achieved remission at week 8, where remission is defined as Montgomery Asberg Depression Rating Scale (MADRS) total score ≤ 10.\n\nMADRS assesses severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Somnolence","Dry mouth","Tremor","Diarrhoea","Dyspepsia"]}}}